

Charity Registration No. 1182637

Company Registration No. CE016951 (England and Wales)

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

**TRUSTEES' REPORT AND
FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED
31 DECEMBER 2019**

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

LEGAL AND ADMINISTRATIVE INFORMATION

Trustees David Oxnam (Chair of Board of Trustees)
Dr Daniel Saunders (Treasurer)
Gayle Routledge
Rachel Wilcox

Chief Executive Ashley Gamble

Charity number 1182637 (England and Wales)
SC049948 (Scotland)

Company number CE016951

Operating name CCLG

Principal address Century House
24 De Montfort Street
Leicester
LE1 7GB

Auditor Newby Castleman LLP
West Walk Building
110 Regent Road
Leicester
LE1 7LT

Bankers HSBC Bank Plc
2-6 Gallowtree Gate
Leicester
LE1 1DA

National Westminster Bank Plc
1 Granby Street
Leicester
LE1 6EJ

Scottish Widows Bank Plc
PO Box 12757
67 Morrison Street
Edinburgh
EH3 8YJ

CAF Bank Ltd
25 Kings Avenue
Kings Hill
Kent
ME19 4JQ

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

CONTENTS

| | Page |
|-----------------------------------|-------------|
| Trustees' report | 1 - 9 |
| Independent auditor's report | 10 - 12 |
| Statement of financial activities | 13 |
| Balance sheet | 14 |
| Statement of cash flows | 15 |
| Notes to the accounts | 16 - 32 |

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT

FOR THE YEAR ENDED 31 DECEMBER 2019

The trustees of The Children's Cancer and Leukaemia Group are pleased to present their annual report and financial statements for the year ended 31 December 2019.

The financial statements have been prepared in accordance with the accounting policies set out in the notes to the accounts and comply with the charity's governing document, the Charities Act 2011 and "Accounting and Reporting by Charities": Statement of Recommended Practice applicable to charities preparing their accounts in accordance with FRS 102.

The financial statements have been prepared to give a true and fair view and have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the regulations but which has since been withdrawn.

OBJECTIVES AND ACTIVITIES

The objectives of The Children's Cancer and Leukaemia Group (CCLG) as defined in the constitution are:

For the public benefit, the relief of sickness and suffering of children, teenagers and young adults with cancer and advancement of education in the field of children, teenagers and young adults with cancer, in particular but not exclusively by:

1. The relief of sickness and promotion and protection of good health by supporting research into the nature, causes, diagnosis, treatment and social consequences of cancer in children, teenagers and young adults, and to publish the useful results of such research.
2. The relief of suffering of children, teenagers and young adults with cancer and their families and carers, through the provision of information and support services to them.
3. The advancement of the education of the public in all areas relating to cancer in children, teenagers and young adults.
4. The advancement of education and clinical practice by the dissemination of knowledge of the latest research and best practice amongst professionals and practitioners engaged in the treatment, care and support of children, teenagers and young adults with cancer.

The main beneficiaries of the work carried out by the charity are children, teenagers and young adults with cancer and their families in the United Kingdom and elsewhere in the world.

CCLG is the UK and Ireland's professional association for all those involved in the treatment and care of children with cancer (including leukaemia). The group has multidisciplinary and multi-professional membership, which continues to grow. At the end of 2019, there were in excess of 1000 members.

Through our membership activities, we provide an active forum for professionals to work together to share best practice and advance education and professional development. Members are able to network with both national and international colleagues for advice and support and receive information and vital updates on specific diseases and treatments. This ensures every child with cancer receives the best possible treatment and care available wherever they live.

Our membership activities include:

- Specialist network groups. These are a core part of our professional activities enabling professionals to work with others who share the same clinical interests.
- Key conferences. We organise a range of meetings each year to ensure members are kept up to date with all the latest developments in cancer care and treatment. Our main annual meeting in January offers an opportunity for all of our members to network with colleagues from across Britain and Ireland.
- Professional voice for children and younger teenagers with cancer in the British Isles. We advise governments and other bodies and ensure that we are represented on important groups or in consultations, for example in the area of NHS commissioning of children's cancer services or the development of NICE quality standards and guidance.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2019

- Our online members' area, a vital hub for professionals involved in the care of children with cancer, providing a wealth of resources and educational opportunities for our membership.

Our members work hard to ensure that children and teenagers have a greater chance of survival and a better life after treatment.

We support children and young people with cancer and their families in a variety of different ways:

- Written by experts, our comprehensive quality-assured range of information booklets and leaflets helps patients and their families understand their diagnosis, treatment and what to expect now and in the future. Our publications are available free of charge to those who need them.
- Our free quarterly magazine, Contact, offers help, support and information for families of children, teenagers and young adults with cancer.
- We also organise informative events for parents and families each year. Since 2014, we have organised the UK Childhood Cancer Conference. This hugely successful event brings together parents, researchers, healthcare professionals and charities to discuss the latest research into childhood cancer and talk about the issues which affect parents.
- Our website is a comprehensive resource of childhood cancer information. In 2018, we added our 'Childhood Cancer Information Hub', bringing together information resources (booklets and leaflets, web pages, film and video content and more) into a single 'one-stop-shop', which is easily searchable and can be filtered by cancer type, audience, etc. We also launched our first animation for children with cancer, a short film based on our booklet 'My brother or sister has cancer', which was well received. Plans are underway to produce additional film and animation content for our website.

The outstanding progress made in cancer treatment is the result of extensive research studies and clinical trials over the last 40 years which now underpin today's standard treatments. During this time, CCLG has played a key role in the success seen in the world of children's cancer so that now over 80% of children are cured.

But there are still some childhood cancers with a poor outlook, and some treatments can have long-lasting and devastating side effects. Further research is vital to improve survival rates and to find kinder treatments.

We fund and support a variety of research into childhood cancers including:

- The CCLG Tissue Bank is the UK's largest collection of tumour, DNA and other tissue samples from childhood cancer patients. Samples enable scientists and researchers to get as close to the disease as possible so they can find new ways of diagnosing children, new treatments and cures for patients.
- We offer funds and grants to launch new research projects and develop new clinical trials.
- We work in partnership with other charities and organisations to support research. We use our research-funding infrastructure, as well as the scientific and medical expertise of our membership, to support smaller charities to meet their research aims. For example, by managing a research funding programme or helping them to identify research to support.
- We can 'ringfence' funds so that our supporters can raise funds towards a cancer-specific research project.
- Our Special Interest Groups provide a forum for discussion and planning of research and bring together potential collaborators. We organise and support scientific meetings where research findings are shared and discussed, and we support our membership to be involved in planning research and attending important meetings through bursaries and sponsorship.
- We support the next generation of childhood cancer researchers through our trainee scheme in partnership with the National Cancer Research Institute. This allows trainee paediatric oncologists to be involved in the development and management of clinical trials, by attending meetings, being mentored by experienced researchers, and gaining insight into research activity.
- In 2017, CCLG was accepted into membership of the Association of Medical Research Charities, demonstrating our commitment to funding high-quality, world class research and confirming the high standard of the processes we use to select and fund research.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2019

We measure our success in achieving our objectives in a number of ways:

- The number of patient information products distributed, and the number of visits to the 'about childhood cancer' section of our website, are some measures used to ascertain our success in supporting patients and their families. We also gather feedback on our information products.
- The number of publications in journals, the number of studies accessing the CCLG Tissue Bank, and the amount of tissue samples banked, are some measures used to ascertain the success of our research programme including the CCLG Tissue Bank.
- The number of members and retention of members are some basic measures used to ascertain how we are supporting the community of professionals we serve through our professional association activities.
- The number of research projects funded and their value, and the outcome of research projects including peer-reviewed papers in scientific journals.

ACHIEVEMENTS AND PERFORMANCE

Conversion to charitable incorporated organisation

During the year, the trustees completed the process of converting the unincorporated charity into a charitable incorporated organisation ("CIO"). Until 31 July 2019, the unincorporated charity had been hosted by the University of Leicester, with the university employing the staff and re-charging the charity for the costs of this, and the university providing subsidised, and more recently donated, office accommodation. The assets and liabilities of the unincorporated charity were transferred to the CIO on 1 August 2019, and from this date the CIO employed the charity's staff directly. The charity also moved its base of operations into new office premises, rented directly by the CIO. Following the transfer, the CIO continues the same activities the unincorporated charity undertook, and the unincorporated charity will be removed from the Charity Commission register. At the same time, a restructuring of the charity's staff team created a senior leadership team to support the chief executive, creating the new posts of Head of Information, Communications and Marketing (filled by internal promotion) and Head of Fundraising (filled by external recruitment).

CCLG continues to go from strength to strength. Following the publication of our new strategic plan in January 2018, covering the years 2018-2025, we continued to work towards our four main goals.

Providing leadership and expertise for the treatment and care of children and young people with cancer

As the UK and Ireland's professional association for those working in the field of paediatric oncology and haematology, CCLG is a leading voice for children's cancer, liaising with community groups, the government and the NHS to influence policies. We use our expertise to improve treatment and care and meet the needs of patients and families. In 2019:

- We continued to organise scientific and educational meetings to share the most up-to-date news, research and information in all areas of treatment and care. Our key event, the annual CCLG Winter Meeting, was the largest to date, bringing together more than 200 members. A number of additional meetings were held throughout the year, including a number of disease-specific education days. For the first time, we held a two-day disease-specific education course, focusing on neuroblastoma, bringing together a faculty of UK and international experts. The success of this event has led to further planned courses of a similar nature in future years.
- We continued to advocate on behalf of both the professional and patient communities, including responding to an NHS England consultation on the future specification of children and young people's cancer services, ensuring that the resulting proposals were the most appropriate in providing safe, effective care for patients.
- We produced and updated a number of clinical treatment guidelines, ensuring standardised, high quality and evidence-based treatment for all children, particularly in diseases where there is currently no open clinical trial.
- We commissioned a significant piece of research into the experience and needs of our membership, which will report back to CCLG in 2020 and shape a strategy for ensuring CCLG continues to meet the evolving needs of our members, and will determine how we ensure our members get the most from their membership, and that we support them in their roles, ultimately benefiting children and young people with cancer.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2019

- We continued to support the next generation of childhood cancer professionals, supporting the Paediatric Oncology Trainees Group to hold two educational meetings and a series of online learning sessions, and by providing funding to enable trainee medics and other healthcare professionals to present their work at conferences and meetings.
- We continued to develop our proposals for improving the collection of data related to childhood cancers to better inform research, treatment decisions and to begin to improve our understanding of the long-term effects of cancer treatment in children.

Improving diagnosis times by increasing awareness

The significance of a delayed diagnosis presents a challenge for primary health care professionals, who are required to triage symptoms that may point to a cancer diagnosis from those which are not and make appropriate onward referrals. Many symptoms associated with cancer are non-specific and are seen every day in general practice, whilst a cancer diagnosis is seen infrequently. Delays in the diagnostic pathway may well lead to more advanced disease at presentation, with subsequent greater risk of death, greater morbidity, and inevitably, distrust of the medical system. There is evidence that tumours presenting in childhood in the UK are larger, at a more advanced stage and require more therapy than those presenting in other parts of Europe. We work to improve diagnosis times for children and young people with cancer. In 2019:

- Our Child Cancer Smart project began the first phase of our work in developing clinical referral guidelines, and public and professional awareness tools, on the signs and symptoms of childhood cancer. The first phase of this project is mostly research focussed, and will lead to a suite of tools for healthcare professionals to aid in the earlier diagnosis of all childhood cancers, as well as awareness campaigns for both professionals and the public on the signs and symptoms of childhood cancer.
- In partnership with The University of Nottingham, planning commenced for the Childhood Cancer Diagnosis Study, funding by the National Institute for Health Research and CCLG. This study will look at the presenting signs and symptoms and the diagnostic pathway for all newly diagnosed children over a two-year period, helping us to further identify key symptoms and work to improve the route to diagnosis for children with a suspected malignancy.
- We continued to work on a referral guide for suspected cancer in children and young people to support general practitioners and other professionals involved in the diagnosis of cancer in this age group, publishing the results of the research underpinning this work, with a view to publishing the final guidance in 2020.

Strengthening our expert information portfolio to support more families of a child with cancer

Looking after a child with cancer can be a scary and lonely experience for families. Our goal is to deliver the right information at the right time and make a positive difference to their daily lives.

We continue to be the leading provider of expert-written, award-winning and quality-assured information about all aspects of childhood cancer, from diagnosis to life when treatment has finished. In 2019:

- We sent more than 20,000 free information booklets and leaflets to hospitals and directly to families during the year. A number of new publications were produced, and further existing publications were reviewed and revised in line with our Information Standard accreditation, demonstrating our commitment to high-quality health information.
- We produced four issues of Contact magazine, a source of information and support for families, with each issue having a circulation in excess of 6,000 copies.
- We continued to add to and improve the health information content of our website, which received almost half a million 'hits' during the year.
- Our annual Childhood Cancer Conference, now in its sixth year, was the largest yet, with over 150 delegates. This unique event brings together parents and family members, researchers and healthcare professionals to hear about the latest advances in childhood cancer and signpost to the range of support available to families.
- During the year we launched a closed Facebook group for parents and carers of children with cancer, allowing them to seek advice and support from those with similar experiences, and, uniquely, 'ask the experts' through posting questions answered by our clinical membership community.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2019

Supporting and funding world-class research

Our aim is to both support and fund world-class research, deepen understanding and foster collaborations across the childhood cancer community. One of our most important areas of work is to offer opportunities for our members to develop scientific networks and belong to a wider research community dedicated to childhood cancer. Our Research Strategy outlines our exciting plans to fund and support innovative world-class research into childhood cancer and recognises the importance of collaboration, both nationally and internationally, to achieve improvements.

- We fund research directly, and work with partner charities to support them to fund the best possible research, using our well-established research funding expertise, experience and infrastructure. In total, between our own research funding and that of the partners we work with, 31 new research projects totalling over £5 million were funded in 2019.
- We continued to work in partnership with The Little Princess Trust to support them to fund the best quality research with a focus on finding better, kinder treatments. The Trust were in a position to increase their available research funding during the year, and following an internal review on how they fund research, found “it was very clear that the most robust and credible route was through CCLG”. During the year, the Trust awarded 24 projects just over £4.5 million, including two much larger grants than previously for bigger programmes of work.
- We also worked in partnership to award a research grant on behalf of The Grace Kelly Childhood Cancer Trust, and awarded a joint grant with Neuroblastoma UK.
- We initiated a Priority Setting Partnership for children’s cancer during the year, co-funded with the Little Princess Trust and under the auspices of the James Lind Alliance (JLA). The JLA is a non-profit making initiative established in 2004. It brings patients, carers and clinicians together in Priority Setting Partnerships (PSPs) to identify and prioritise the top 10 unanswered questions or evidence uncertainties that they agree are the most important. The aim of this is to make sure that health research funders are aware of the issues that matter most to the people who need to use the research in their everyday lives. The children’s cancer PSP will complete its work programme over the next two years to define the top 10 research priorities in childhood cancer, which will feed into CCLG’s future research strategy.
- We invested in a new online research grant application and management system during the year, which will improve the experience of applying for a research grant from CCLG, and help us to improve the efficiency and quality of our research-funding processes.
- We appointed our first research staff member to develop and guide our research activity and manage our research programme.

Fundraising

All of our work is dependent on the generosity of our supporters. A programme of fundraising underpins our ability to fund research, support patients and families and improve treatment and care for children and young people with cancer. In 2019:

- Our Special Named Funds programme continues to grow. After their cancer experiences, families sometimes consider setting up their own charity. For many, our Special Named Funds may be a great alternative. We support families to achieve their fundraising objectives, while taking away the administrative burden of setting up and running a charity. At the end of the year, there were approximately 40 Special Named Fund at CCLG, each raising funds to support research into a specific type of childhood cancer.
- We appointed our first Head of Fundraising, to develop and implement a new fundraising strategy for CCLG and to lead, guide and support our fundraising team, which also expanded during the year.

Teenagers and Young Adults with Cancer (TYAC)

Following the completion of our merger with TYAC in 2018, during the year we developed and launched a new strategy for the work of TYAC, setting out how we would continue to drive improvements in teenage and young adult cancer care, and support the development of professionals working in the specialised field. In 2019:

- We held a well-attended two-day conference for TYA cancer professionals
- Launched our new strategy for TYAC and began to plan for new workstreams in both research and health information for this age group

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2019

- Began to develop a fundraising strategy for this aspect of our work, with a focus on raising funds to support research

Fundraising policy

We are reliant on donations to fund our vital work. Without the generosity of the public we would not be able to continue providing support to children and young people diagnosed with cancer, and their families, nor fund research into childhood cancer.

We believe that it is essential that we are clear and open about how we raise our funds and about the range of ways people can get involved and support our work.

People raise money for us in many different ways, including through taking part in sporting events, organising events in their local community, or fundraising at their place of work. We also provide opportunities for people to fundraise through providing access to places in key events, such as the London Marathon, and through providing fundraising materials.

Our supporters can sign up to make a regular donations, or to play our lottery which we launched last year. We work with a number of corporate partners, and have received support from charitable trusts and foundations, and through grants from other charities.

We do not carry out door-to-door fundraising, nor do we use street fundraising to sign up supporters to regular donations. Currently, none of our fundraising activities are conducted on our behalf by professional fundraising agencies.

CCLG is registered with the Fundraising Regulator. We are committed to adhering to the Code of Fundraising Practice. During the year, we received no complaints about our fundraising activities. Regular updates are provided to our board of trustees to ensure that they have a good oversight of our activities.

FINANCIAL REVIEW

Transactions for the year ended 31 December 2019 fall into roughly the same categories as in previous years. Income generally consists of donations and fundraising income, subscriptions (comprising individual membership subscriptions and hospital subscriptions for health information), registration fees for meetings and events, and funding from partner charities such as The Little Princess Trust to support research projects awarded through strategic partnerships. We are grateful to CLIC Sargent and Teenage Cancer Trust for their continued support of TYAC activity, and to the University of Leicester for donated premises and services until the charity's transfer to a CIO on 1 August 2019.

The major items of expenditure for CCLG remain staff salaries, professional meeting and event costs, the costs associated with the production of health information, and the awarding of research grants.

Staffing costs represent a significant financial commitment, but our small, expert staff team is also responsible for the achievement of the majority of our charitable objectives. Staffing levels are kept under review, with the small, efficient team carrying out and coordinating the considerable activities of the charity.

Our overall income increased by £4,553,183 during 2019, compared with the year ending December 2018. Primarily this was due to a significant increase in research grants awarded by the Little Princess Trust. Our direct fundraising income has increased by £381,900 during the year. The Trustees are pleased we have continued to see growth in the fundraising income stream as a result of investment in fundraising activity.

CCLG has a number of restricted funds. The restricted funds are contained within the single HSBC account, but separate internal records are kept according to requirements for restriction, i.e. tumour specific donations or donations for a specific piece of work. The restricted funds are ring-fenced to support specific projects or areas of activity and cannot be used to support the general running costs of the organisation.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2019

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Expenditure increased in 2019 by £4,847,416 compared to 2018. The primary reason for this increase was the awarding of a larger number of research grants, and in particular through funding from the Little Princess Trust as described above.

Reserves Policy

The trustees continue to consider the appropriate balance of financial stability and investment in charitable activity. At the end of the year we have reviewed our reserves policy for CCLG and aim to hold a target level of free reserves (unrestricted funds less tangible fixed assets) of £500,000, which the trustees consider to be approximately six months of core expenditure, including staff salaries, accommodation costs and general running costs. This is a decrease in our previous reserves policy, as the trustees recognise the need to ensure appropriate investment in key charitable activities and infrastructure improvements to support the efficient running of the charity. Total reserves at 31 December 2019 were £1,811,304 of which £1,305,739 are restricted and £505,565 are unrestricted. As at 31 December 2019 the charity's free reserves totalled £454,415. However, at the time of writing the coronavirus pandemic is having a significant effect on our ability to raise funds and on our income. The Trustees are mindful that we may need to use reserves to ensure core operations of the charity continue, and keep the developing situation under review.

The impact of the COVID-19 pandemic

Like many charities, the impact of the COVID-19 pandemic in 2020 has had a huge impact on CCLG, both in our operations and our income generation. With many major fundraising events – notably the London Marathon – postponed and then cancelled, as well as the period of 'lockdown' and subsequent social distancing and other regulations preventing many types of fundraising events from being organised, we expect our income from fundraising to be reduced significantly this year. The inability to hold 'in-person' meetings and events means that the majority of our educational and scientific meetings and conferences for professionals have been cancelled for the year. This will also result in a decrease in income, although this is mitigated to some extent by the corresponding decrease in expenditure on the cost of holding such events.

The Trustees and the Chief Executive have liaised closely during this time to try and mitigate the impact on the charity as much as possible to secure the future of the charity and ensure the wellbeing of staff. We have used the government's Coronavirus Job Retention Scheme ("furlough scheme"), taking the difficult decision to furlough a number of our staff team, and then bring them back on reduced hours under the 'flexible furlough' scheme from July, to support the costs of employing staff during the crisis. This necessitated focusing our work on the most important projects. We have put a recruitment freeze in place and not progressed with the hiring of additional staff planned for during the year. We will also naturally reduce expenditure where planned activities have been unable to take place due to the pandemic, for example our usual travel expenditure for both staff and members will be reduced due to little business-related travel taking place for a significant part of the year. We have also brought forward plans for a number of activities, including 'virtual fundraising events', to begin to rebuild our income in the last quarter of 2020.

Supporting our staff throughout this period has been a key priority for the Trustees and Senior Leadership Team. Our staff team is at the heart of what we do and are passionate about the impact CCLG has on children with cancer and their families. We recognise that our committed staff team also have lives outside of their work for CCLG which will have also been affected. The Trustees and Senior Leadership Team are extremely grateful for the dedication of the team, and how they have adapted to the current situation to ensure our vital work continues. We asked all staff to work from home, where possible, from early March, and offered flexible work patterns to suit the new circumstances of our team members. We offered weekly online 'social catch-ups' for team members as well as ensuring regular updates were provided directly in team meetings, and through our internal social media platform. Following the relaxation of some restrictions, we have worked hard to ensure a 'COVID secure workplace' and are now beginning to make plans for staff to return to the office, along with continuing to support employees in new ways of working, including continued working from home where appropriate, and flexible working patterns.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2019

Investment policy

The Trustees previously planned to review our investments during 2019 and consider the most appropriate way of managing these, balancing cashflow, risk and reward. Given the uncertainty around the financial impact of the UK leaving the European Union, no further action has been taken on investments. Management accounts are produced for the trustees, and a cashflow forecast considerably facilitates management and prediction of charity income.

Risk Management

CCLG is also aware of the requirement to carry out a risk review of its activities. The trustees reviewed the risks the charity faces during the year. A Risk Register is in operation, documenting the systems in place to mitigate those risks, and is kept under review by the trustees.

FUTURE ACTIVITIES

All future activities planned are designed to ensure that CCLG continues to fulfil its objectives with children and young people with cancer, and their families, as the ultimate beneficiaries.

As the membership of CCLG continues to grow, so does the activity our members are involved in. Our specialist network groups continue to be increasingly active, supporting our activities and provide specialist advice to commissioners of health care services and others. The Executive continues to consider ways that CCLG can advance education and professional development, and share and guide best practice.

Following the launch of our research strategy, and the successful awarding of research grants during the year, we aim to further increase our support for research during 2020. We will also review our research strategy in 2020.

We plan to continue to develop our range of patient/parent information products in response to demand and specific needs identified by both end users and professionals.

We also aim to continue raising awareness of CCLG and its activities, with a view to continuing to increase the income and resources available to us to meet our objectives.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Children's Cancer and Leukaemia Group (CCLG) was established in 1977 and became a registered charity (number 286669) in 1983. As described above, a new CIO (registration number 1182637) was formed in 2019, with the activities, assets and liabilities of the previous charity transferred to the CIO. The charity's governing instrument is the Constitution and the CIO was first registered in February 2019.

The board of trustees is independent of the CCLG membership. The board of trustees is responsible for managing the charity finances in support of the objectives defined by the CCLG Executive. There are a minimum of two and a maximum of eight trustees. One of the trustees will be the CCLG Treasurer, an elected member of the CCLG Executive, providing a link between these two groups.

If a vacancy arises, the trustees may appoint any eligible person as a trustee. In selecting individuals for appointment as trustees, the trustees will consider the skills, knowledge and experience needed for the effective running of the charity.

Upon appointment, trustees are provided with an induction to the charity. This consists of a briefing paper, as well as meetings with the Chair, CEO, and others as deemed appropriate. Regard is given to the training and development needs of any trustees that may arise.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

TRUSTEES' REPORT (CONTINUED)

FOR THE YEAR ENDED 31 DECEMBER 2019

The board of trustees meets quarterly and is supported by staff from the CCLG Coordinating Centre. Four meetings were held in 2019. The trustees come from a range of professional backgrounds, and bring new skills and highly relevant experience.

Trustees serving during the year were:

David Oxnam

Dr Daniel Saunders

Lorenzo Moruzzi (resigned 31 July 2019)

Gayle Routledge

Rachel Wilcox

The Chief Executive is responsible for the day to day operation of the charity on behalf of the trustees. The remuneration of key management is reviewed annually by the board and is set against established pay scales, benchmarked in comparison with similar sized entities including both charities and medical professional associations. The trustees give their time freely and no remuneration was paid in the year. Details of trustee expenses are disclosed in note 11 to the accounts.

STATEMENT OF TRUSTEES' RESPONSIBILITIES

The trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

The law applicable to charities in England and Wales requires the trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources of the charity for that period. In preparing these financial statements, the trustees are required to:

- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the charities SORP 2019 (FRS 102);
- make judgements and estimates that are reasonable and prudent;
- state whether applicable accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charity will continue in operation.

The trustees are responsible for keeping proper adequate accounting records that disclose with reasonable accuracy at any time the financial position of the charity and enable them to ensure that the financial statements comply with the Charities Act 2011, the Charity (Accounts and Reports) Regulations 2008 and the provisions of the constitution. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The trustees are responsible for the maintenance and integrity of the charity and financial information included on the charity's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

David Oxnam

Chair of the board of trustees

Dated: 22 October 2020

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Opinion

We have audited the financial statements of The Children's Cancer and Leukaemia Group (the 'charity') for the year ended 31 December 2019 which comprise the statement of financial activities, the balance sheet, the statement of cash flows and the notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including FRS 102 *The Financial Reporting Standard applicable in the UK and Republic of Ireland* (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charity's affairs as at 31 December 2019, and of its incoming resources and application of resources, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charity in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs (UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
- the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the charity's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.

Other information

The other information comprises the information included in the trustee's report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 require us to report to you if, in our opinion:

- the information given in the financial statements is inconsistent in any material respect with the Trustees' Report; or
- sufficient accounting records have not been kept; or
- the financial statements are not in agreement with the accounting records; or
- we have not received all the information and explanations we require for our audit.

Responsibilities of trustees

As explained more fully in the trustees' responsibilities statement set out on page 9, the trustees are responsible for the preparation of financial statements which give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the charity or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with regulations made under section 154 of that act.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: <http://www.frc.org.uk/auditorsresponsibilities>. This description forms part of our auditor's report.

Other matters which we are required to address

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their financial statements in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

This has been done in order for the financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

INDEPENDENT AUDITOR'S REPORT (CONTINUED)

TO THE TRUSTEES OF THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with Part 4 of the Charities (Accounts and Reports) Regulations 2008. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity and the charity's trustees as a body, for our audit work, for this report, or for the opinions we have formed.

Newby Castleman LLP

Chartered Accountants
Statutory Auditor
West Walk Building
110 Regent Road
Leicester
LE1 7LT

28 October 2020

Newby Castleman LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

STATEMENT OF FINANCIAL ACTIVITIES

FOR THE YEAR ENDED 31 DECEMBER 2019

| | Notes | Unrestricted funds £ | Restricted funds £ | Total 2019 £ | Total 2018 £ |
|---|-------|----------------------------|--------------------------|--------------------|--------------------|
| Income from | | | | | |
| Donations and legacies | 3 | 586,115 | 545,144 | 1,131,259 | 749,359 |
| Charitable activities | 4 | 374,676 | 4,756,988 | 5,131,664 | 963,029 |
| Investments | 5 | 8,841 | - | 8,841 | 6,193 |
| Total | | 969,632 | 5,302,132 | 6,271,764 | 1,718,581 |
| Expenditure on | | | | | |
| Raising funds | 6 | 253,005 | - | 253,005 | 236,956 |
| Charitable activities | 7 | 836,231 | 5,242,448 | 6,078,679 | 1,247,312 |
| Total | | 1,089,236 | 5,242,448 | 6,331,684 | 1,484,268 |
| Net (expenditure)/income for the year/ Net movement in funds | | (119,604) | 59,684 | (59,920) | 234,313 |
| Reconciliation of funds | | | | | |
| Total funds brought forward | | 625,169 | 1,246,055 | 1,871,224 | 1,636,911 |
| Total funds carried forward | | 505,565 | 1,305,739 | 1,811,304 | 1,871,224 |

All income and expenditure derive from continuing activities.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

BALANCE SHEET

AS AT 31 DECEMBER 2019

| | Notes | 2019 £ | £ | 2018 £ | £ |
|--|-------|------------------|-------------------------|------------------|-------------------------|
| Fixed assets | | | | | |
| Tangible assets | 13 | | 51,150 | | 37,759 |
| Current assets | | | | | |
| Stocks | 14 | 30,514 | | 55,429 | |
| Debtors | 15 | 2,781,938 | | 110,407 | |
| Cash at bank and in hand | | 2,776,343 | | 2,541,805 | |
| | | <u>5,588,795</u> | | <u>2,707,641</u> | |
| Liabilities | | | | | |
| Creditors: amounts falling due within one year | 16 | (1,743,072) | | (874,176) | |
| Net current assets | | | <u>3,845,723</u> | | <u>1,833,465</u> |
| Total net assets | | | <u>3,896,873</u> | | <u>1,871,224</u> |
| Creditors: amounts falling due after more than one year | 17 | | (2,085,569) | | - |
| Total net assets | | | <u><u>1,811,304</u></u> | | <u><u>1,871,224</u></u> |
| The funds of the charity | | | | | |
| Restricted funds | 20 | 1,305,739 | | 1,246,055 | |
| Unrestricted funds | 21 | 505,565 | | 625,169 | |
| Total charity funds | | | <u><u>1,811,304</u></u> | | <u><u>1,871,224</u></u> |

The financial statements were approved and authorised for issue by the board of trustees on 22 October 2020 and are signed on its behalf by:

David Oxnam (Chair of Board of Trustees)
Trustee

The notes on pages 16 - 32 form part of these financial statements.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

STATEMENT OF CASH FLOWS

FOR THE YEAR ENDED 31 DECEMBER 2019

| | Notes | 2019 £ | £ | 2018 £ | £ |
|---|-------|-----------|-----------|-----------|-----------|
| Cash flows from operating activities | | | | | |
| Cash generated from/(absorbed by) operations | 26 | | 278,848 | | (38,826) |
| Investing activities | | | | | |
| Purchase of tangible fixed assets | | (53,151) | | - | |
| Interest received | | 8,841 | | 6,193 | |
| Net cash (used in)/generated from investing activities | | | (44,310) | | 6,193 |
| Net increase/(decrease) in cash and cash equivalents | | | 234,538 | | (32,633) |
| Cash and cash equivalents at beginning of year | | | 2,541,805 | | 2,574,438 |
| Cash and cash equivalents at end of year | | | 2,776,343 | | 2,541,805 |

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2019

1 Accounting policies

Charity information

The Children's Cancer and Leukaemia Group is governed by its Constitution.

1.1 Basis of preparation

The charity is a public benefit entity as defined by FRS102. These financial statements have been prepared in accordance with: The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland ("FRS 102"), Accounting and Reporting by Charities: the Statement of Recommended Practice for charities applying FRS 102 (2019), the Charities Act 2011 and UK Generally Accepted Accounting Practice.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The financial statements are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below. These policies have been consistently applied.

On 1 August 2019 the charity converted from an unincorporated charity to a charitable incorporated organisation. The charity met the criteria for merger accounting as defined in the FRS 102 SORP and as such this is treated as a merger.

1.2 Going concern

At the time of approving the financial statements, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. Thus the trustees continue to adopt the going concern basis of accounting in preparing the financial statements.

1.3 Charitable funds

Unrestricted funds are available for use at the discretion of the trustees in furtherance of their charitable objectives unless the funds have been designated for other purposes.

Designated funds are unrestricted funds of the charity that the trustees have decided at their discretion to set aside for specific purposes. The aim and use of each designated fund is set out in the notes to the financial statements.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The cost of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

1.4 Income recognition

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation, unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2019

1 Accounting policies

(Continued)

For legacies, income is recognised and included in the financial statements when all of the following criteria are met:

- the charity has entitlement to the funds;
- any performance conditions attached to the item(s) of income have been met or are fully within the control of the charity;
- there is sufficient certainty that receipt of the income is considered probable; and
- the amount can be measured reliably.

Where legacies have been notified to the charity but the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Donated facilities and donated services are recognised as income at their fair value when their economic benefit is probable, it can be measured reliably and the charity has control over the item. Fair value is determined on the basis of the value of the gift to the charity. For example the amount the charity would be willing to pay in the open market for such facilities and services. A corresponding amount is recognised in expenditure.

Income from charitable activities includes income received from grants, registration fees for meetings, member subscriptions and publication payments. Such income is recognised at fair value when the charity has entitlement after any performance conditions have been met, it is probable that the income will be received and the amount can be measured with reliability. If entitlement is not met, then the amounts are deferred.

Investment income is earned through holding assets for investment purposes. It comprises bank interest and is recognised on an accruals basis.

1.5 Expenditure recognition

All expenditure, including the awarding of grants, is accounted for on an accruals basis and has been classified under headings that aggregate all costs relating to the category. Expenditure is recognised when there is a legal or constructive obligation to make payments to third parties, it is probable that settlement will be required and the amount of the obligation can be measured reliably. It is recognised under the following headings:

- Costs of raising funds includes costs incurred in seeking donations, grants and legacies, website costs and advertising.
- Expenditure on charitable activities includes research, educational activities and professional association activities to further the delivery of the objectives of the charity.

1.6 Support costs

Support costs are those that assist the work of the charity but do not directly represent charitable activities and costs of raising funds and include office costs, governance costs and administrative payroll costs. They are incurred directly in support of expenditure in line with the objectives of the charity. Support costs are allocated to costs of raising funds and expenditure on charitable activities on a basis consistent with use of the resources.

The analysis of these costs is included in note 10.

1.7 Tangible fixed assets

Tangible fixed assets are measured at cost, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost of assets less their residual values over their useful lives on the following bases:

| | |
|--|------------|
| Short leasehold improvements | 5 years |
| Computer equipment, furniture and fixtures | 5-10 years |

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2019

1 Accounting policies

(Continued)

1.8 Stocks

Stocks include merchandise stock and educational literature. Stocks that are held for resale are stated at the lower of cost and estimated selling price. Stocks held for distribution as part of the charity's activities are valued at their service potential, which the charity considers to be the cost of the materials.

1.9 Cash and cash equivalents

Cash and cash equivalents include cash in hand, deposits held at call with banks and other short-term liquid investments with original maturities of three months or less.

1.10 Financial instruments

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Debtors and creditors with no stated interest rate and receivable or payable within one year are measured at transaction price. Any losses arising from impairment are recognised in the SOFA.

1.11 Employee benefits

When employees have rendered service to the charity, short-term employee benefits to which the employees are entitled are recognised at the undiscounted amount expected to be paid in exchange for that service.

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

1.12 Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

2 Critical accounting estimates and judgements

In the application of the charity's accounting policies, the trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

The trustees do not consider there to be any key sources of estimates or uncertainty that have a significant effect on the amounts recognised in the financial statements.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2019

3 Income from donations and legacies

| | Unrestricted funds £ | Restricted funds £ | Total 2019 £ | Total 2018 £ |
|----------------------------|----------------------------|--------------------------|--------------------|--------------------|
| Donations | 445,686 | 545,144 | 990,830 | 704,021 |
| Legacies | 117,452 | - | 117,452 | 5,948 |
| Donated goods and services | 22,977 | - | 22,977 | 39,390 |
| | <u>586,115</u> | <u>545,144</u> | <u>1,131,259</u> | <u>749,359</u> |
| Unrestricted funds | | | | 463,459 |
| Restricted funds | | | | 285,900 |
| | | | | <u>749,359</u> |

4 Income from charitable activities

| | Unrestricted funds £ | Restricted funds £ | Total 2019 £ | Total 2018 £ |
|---|----------------------------|--------------------------|--------------------|--------------------|
| Registration fees for meetings | 152,486 | 13,723 | 166,209 | 63,627 |
| Grant income for research and operations | 73,000 | 4,743,265 | 4,816,265 | 747,853 |
| Member subscriptions and publication payments | 149,190 | - | 149,190 | 151,549 |
| | <u>374,676</u> | <u>4,756,988</u> | <u>5,131,664</u> | <u>963,029</u> |
| Unrestricted funds | | | | 271,881 |
| Restricted funds | | | | 691,148 |
| | | | | <u>963,029</u> |

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2019

5 Income from investments

| | Unrestricted funds £ | Restricted funds £ | Total 2019 £ | Total 2018 £ |
|--------------------|----------------------------|--------------------------|--------------------|--------------------|
| Interest | 8,841 | - | 8,841 | 6,193 |
| | | | | |
| Unrestricted funds | | | | 6,193 |
| Restricted funds | | | | - |
| | | | | 6,193 |

6 Expenditure on raising funds

| | Unrestricted funds £ | Restricted funds £ | Total 2019 £ | Total 2018 £ |
|--|----------------------------|--------------------------|--------------------|--------------------|
| <u>Cost of raising funds</u> | | | | |
| Virgin Money Giving deductions | 11,195 | - | 11,195 | 12,556 |
| Website | 2,588 | - | 2,588 | 5,463 |
| Fundraising, marketing and publicity costs | 112,868 | - | 112,868 | 139,779 |
| Support costs (note 10) | 126,354 | - | 126,354 | 79,158 |
| | 253,005 | - | 253,005 | 236,956 |
| | | | | |
| Unrestricted funds | | | | 235,358 |
| Restricted funds | | | | 1,598 |
| | | | | 236,956 |

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2019

7 Expenditure on charitable activities

| | Activities undertaken directly note 8 £ | Grant funding note 9 £ | Support Costs note 10 £ | Total 2019 £ | Total 2018 £ |
|---------------------------------------|---|---------------------------------|----------------------------------|--------------------|--------------------|
| Support for research | 65,849 | 5,205,322 | 128,113 | 5,399,284 | 688,079 |
| Information for patients and families | 49,002 | - | 191,808 | 240,810 | 186,582 |
| Improving treatment and care | 242,739 | - | 195,846 | 438,585 | 372,651 |
| | <u>357,590</u> | <u>5,205,322</u> | <u>515,767</u> | <u>6,078,679</u> | <u>1,247,312</u> |
| Unrestricted funds | | | | 836,231 | 633,342 |
| Restricted funds | | | | 5,242,448 | 613,970 |
| | | | | <u>6,078,679</u> | <u>1,247,312</u> |

8 Expenditure on activities undertaken directly

| | Support for research £ | Information for patients and families £ | Improving treatment and care £ | Total 2019 £ | Total 2018 £ |
|-----------------------------------|------------------------------|--|---|--------------------|--------------------|
| Staff costs | 3,466 | - | - | 3,466 | - |
| Other tumour specific expenditure | 59,795 | - | - | 59,795 | 13,709 |
| Contact magazine expenses | - | 9,760 | - | 9,760 | 8,720 |
| Other publication expenses | - | 35,587 | - | 35,587 | 6,838 |
| Website | 2,588 | 3,655 | 3,881 | 10,124 | 30,956 |
| Cost of meetings | - | - | 193,660 | 193,660 | 96,188 |
| Travel expenses | - | - | 17,887 | 17,887 | 23,660 |
| Other expenses | - | - | 27,311 | 27,311 | 22,207 |
| | <u>65,849</u> | <u>49,002</u> | <u>242,739</u> | <u>357,590</u> | <u>202,278</u> |

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2019

9 Expenditure on grant funding

| | Support for research | Information for patients and families | Professional association activities | Total 2019 | Total 2018 |
|-------------------------------|-------------------------|---|---|------------------|----------------|
| | £ | £ | £ | £ | £ |
| Grants to institutions: | | | | | |
| University of Birmingham | 481,477 | - | - | 481,477 | - |
| University of Surrey | 50,286 | - | - | 50,286 | - |
| Newcastle University | 500,944 | - | - | 500,944 | 140,500 |
| UCL Institute of Child Health | 562,149 | - | - | 562,149 | - |
| University of Sheffield | 72,656 | - | - | 72,656 | 98,111 |
| University of Nottingham | 1,302,800 | - | - | 1,302,800 | 133,016 |
| University of Ulster | 74,933 | - | - | 74,933 | - |
| University of Bristol | 198,557 | - | - | 198,557 | 99,986 |
| Queen's University Belfast | 74,997 | - | - | 74,997 | 98,712 |
| Great Ormond Street | 170,366 | - | - | 170,366 | - |
| University of Southampton | 111,236 | - | - | 111,236 | - |
| University Hospital of Wales | 71,490 | - | - | 71,490 | - |
| Genome Research Limited | 950,820 | - | - | 950,820 | - |
| University of Glasgow | 98,793 | - | - | 98,793 | - |
| University of Cambridge | - | - | - | - | 18,047 |
| Institute of Cancer Research | 275,103 | - | - | 275,103 | - |
| University of Leeds | 205,715 | - | - | 205,715 | - |
| University of Manchester | 3,000 | - | - | 3,000 | - |
| | <u>5,205,322</u> | <u>-</u> | <u>-</u> | <u>5,205,322</u> | <u>588,372</u> |

The charity awards grants for specific research projects to various institutions, as part of their charitable activities.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2019

10 Expenditure on support costs

| | Basis of allocation | 2019 £ | 2018 £ |
|---------------------------------|---------------------|----------------|----------------|
| Staff costs | *1 | 456,598 | 423,028 |
| Depreciation & loss on disposal | *1 | 39,760 | 14,944 |
| Occupancy expenses | *1 | 97,589 | 56,773 |
| Postage | *1 | 20,265 | 17,620 |
| Staff training | *1 | 6,985 | 2,954 |
| Professional fees | *1 / *2 | 20,924 | 20,501 |
| | | <u>642,121</u> | <u>535,820</u> |
| Analysed between | | | |
| Raising funds | | 126,354 | 79,158 |
| Charitable activities | | 515,767 | 456,662 |
| | | <u>642,121</u> | <u>535,820</u> |

*1 Support costs, excluding governance costs, have been allocated as follows:

| | |
|---------------------------------------|------------------|
| <i>Cost of raising funds</i> | 20% (2018 - 15%) |
| <i>Charitable activities</i> | |
| Support for research | 20% (2018 - 15%) |
| Information for patients and families | 30% (2018 - 30%) |
| Improving treatment and care | 30% (2018 - 40%) |

*2 Professional fees include governance costs of £10,352 (2018 - £8,100). Governance costs have been allocated as follows:

| | |
|---------------------------------------|-----|
| <i>Charitable activities</i> | |
| Support for research | 17% |
| Information for patients and families | 22% |
| Improving treatment and care | 61% |

The amount charged to the SOFA in respect of auditor's remuneration was £8,580 (2018 - £8,100).

11 Trustees

None of the trustees (or any persons connected with them) received any remuneration or benefits during the year. 3 of the trustees were reimbursed for travel expenses amounting to £1,757 (2018 - 2 trustees were reimbursed for travel expenses of £676).

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2019

12 Employees

Number of employees

The average monthly number of employees during the year was:

| | 2019 Number | 2018 Number |
|-------|----------------|----------------|
| Total | 15 | 15 |

Employment costs

| | 2019 £ | 2018 £ |
|--------------------|-----------|-----------|
| Wages and salaries | 460,064 | 423,028 |

Staff working for the charity were employed directly by the University of Leicester until 1 August 2019. Their salary costs were recharged to the charity, and totalled £249,002 (2018 - £423,028).

The number of employees whose annual remuneration was £60,000 or more were:

| | 2019 Number | 2018 Number |
|-------------------|----------------|----------------|
| £60,001 - £70,000 | 1 | - |

13 Tangible fixed assets

| | Short leasehold improvements £ | Computer equipment, furniture and fixtures £ | Total £ |
|------------------------------------|---|--|------------|
| Cost | | | |
| At 1 January 2019 | 56,253 | 22,079 | 78,332 |
| Additions | - | 53,151 | 53,151 |
| Disposals | (56,253) | (12,028) | (68,281) |
| At 31 December 2019 | - | 63,202 | 63,202 |
| Depreciation and impairment | | | |
| At 1 January 2019 | 32,304 | 8,269 | 40,573 |
| Depreciation charged in the year | - | 9,627 | 9,627 |
| Eliminated in respect of disposals | (32,304) | (5,844) | (38,148) |
| At 31 December 2019 | - | 12,052 | 12,052 |
| Carrying amount | | | |
| At 31 December 2019 | - | 51,150 | 51,150 |
| At 31 December 2018 | 23,949 | 13,810 | 37,759 |

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2019

| | | | |
|-----------|--|------------------|----------------|
| 14 | Stocks | 2019 | 2018 |
| | | £ | £ |
| | Merchandise stock | 10,659 | 18,600 |
| | Educational literature | 19,855 | 36,829 |
| | | <u>30,514</u> | <u>55,429</u> |
| 15 | Debtors | 2019 | 2018 |
| | | £ | £ |
| | Amounts falling due within one year: | | |
| | Trade debtors | 81,352 | 3,381 |
| | Grant debtors | 1,045,933 | - |
| | Rent deposit | 16,200 | - |
| | Prepayments and accrued income | 265,511 | 107,026 |
| | | <u>1,408,996</u> | <u>110,407</u> |
| | Amounts falling due after more than one year: | | |
| | Grant debtors | 1,372,942 | - |
| | | <u>1,372,942</u> | <u>-</u> |
| | Total debtors | <u>2,781,938</u> | <u>110,407</u> |
| 16 | Creditors: amounts falling due within one year | 2019 | 2018 |
| | | £ | £ |
| | Deferred income (see note 18) | 19,095 | 7,410 |
| | Trade creditors | 23,115 | 14,276 |
| | Grant creditors | 1,681,177 | 723,939 |
| | Accruals | 19,685 | 128,551 |
| | | <u>1,743,072</u> | <u>874,176</u> |
| 17 | Creditors: amounts falling due after more than one year | 2019 | 2018 |
| | | £ | £ |
| | Grant creditors | 2,085,569 | - |
| | | <u>2,085,569</u> | <u>-</u> |

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2019

18 Deferred income

| | 2019 £ | 2018 £ |
|---|-----------|-----------|
| Total deferred income at 1 January 2019 | 7,410 | 10,434 |
| Amounts released into incoming resources | (7,410) | (10,434) |
| Amounts deferred in year | 19,095 | 7,410 |
| Total deferred income at 31 December 2019 | 19,095 | 7,410 |

Deferred income comprises advanced registration fees for meetings.

19 Retirement benefit schemes

Defined contribution schemes

The charity operates a defined contribution pension scheme for all qualifying employees.

The amount recognised as an expense in the period was £24,231 (2018 - £Nil), of which £24,231 was unrestricted.

20 Restricted funds

The income funds of the charity include restricted funds which comprise the following unexpended balances of donations and grants held on trust for specific purposes:

| | Balance at 1 January 2019 £ | Movement in funds Income Expenditure | | Balance at 31 December 2019 £ |
|---|--------------------------------------|---|-------------|--|
| | | £ | £ | |
| Tumour specific funds | 985,978 | 543,783 | (599,534) | 930,227 |
| CCLG Prize | 354 | - | (50) | 304 |
| General research fund | 2,122 | 860 | - | 2,982 |
| Adam Hay fund | 11,776 | 220 | (135) | 11,861 |
| CCLG Senior Members Group | 7 | - | - | 7 |
| PODC | 3,562 | 1,851 | (2,096) | 3,317 |
| POTG | 6,231 | 6,679 | (10,771) | 2,139 |
| The Little Princess Trust fund | 6,165 | 4,507,368 | (4,507,333) | 6,200 |
| Treatment Guidelines fund | 18,948 | - | (287) | 18,661 |
| TYAC Lisa Thaxter | 45,712 | - | (300) | 45,412 |
| Child Cancer Smart | 165,000 | 20,000 | (10,056) | 174,944 |
| PORT | 200 | - | - | 200 |
| CCLG Research Network Partner Charity | - | 152,656 | (80,000) | 72,656 |
| CYP Coalition Activity | - | 12,500 | (3,466) | 9,034 |
| Neuroblastoma Nursing Group | - | 6,000 | - | 6,000 |
| Childhood Cancer Priority Setting Partnership | - | 50,000 | (28,420) | 21,580 |
| PODC - Iraq Fund | - | 215 | - | 215 |
| | 1,246,055 | 5,302,132 | (5,242,448) | 1,305,739 |

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2019

20 Restricted funds

(Continued)

| | Balance at 1 January 2018 | Income | Expenditure | Balance at 31 December 2018 |
|--------------------------------|---------------------------------|----------------|------------------|-----------------------------------|
| | £ | £ | £ | £ |
| Tumour specific funds | 822,819 | 229,788 | (66,629) | 985,978 |
| CCLG Prize | 354 | - | - | 354 |
| General research fund | 2,122 | - | - | 2,122 |
| Adam Hay fund | 18,114 | 400 | (6,738) | 11,776 |
| CCLG Senior Members Group | 7 | - | - | 7 |
| PODC | 1,644 | 3,295 | (1,377) | 3,562 |
| POTG | 8,700 | 5,320 | (7,789) | 6,231 |
| The Little Princess Trust fund | - | 526,833 | (520,668) | 6,165 |
| Treatment Guidelines fund | 20,161 | - | (1,213) | 18,948 |
| Data Collection Project fund | 10,654 | - | (10,654) | - |
| TYAC Lisa Thaxter | - | 46,212 | (500) | 45,712 |
| Child Cancer Smart | - | 165,000 | - | 165,000 |
| PORT | - | 200 | - | 200 |
| | <u>884,575</u> | <u>977,048</u> | <u>(614,568)</u> | <u>1,246,055</u> |

Tumour specific funds

Represents income received from donors with a specific request that the funds are used in support of grants for a particular tumour type.

CCLG Prize

Represents income received from donors to fund the CCLG Prize.

General research fund

Represents income received from donors with a specific request that the funds are used for research purposes.

Adam Hay fund

This fund has been established to continue work done by the Adam Hat's charity (which merged with CCLG in 2011) in neuroblastoma research and psychological support for children and families.

CCLG Senior Members Group

Represents income received from the Senior Members' Group to be used for their activities.

PODC

Represents income received from donors to be used for the Paediatric Oncology in Developing Countries (PODC).

POTG

Represents income received from donors to be used for the Paediatric Oncology Trainees' Group (POTG).

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2019

20 Restricted funds

(Continued)

The Little Princess Trust fund

Represents income received from The Little Princess Trust to fund future instalments of research grants awarded.

Treatment Guidelines fund

Represents a grant received for the development of rare endocrine tumour guidelines.

TYAC Lisa Thaxter

Represents income received for providing and supporting education and training to professionals working in the field of teenage and young adult cancer. This was previously a restricted fund in TYAC and has transferred to CCLG as part of the closure of TYAC, with the same restrictions maintained.

Child Cancer Smart

Represents income received for a research programme, guideline development and awareness raising focusing on earlier diagnosis of childhood cancer.

PORT

Represents income received for the Paediatric Oncology Reference Team, a group of parents of children with cancer who review clinical trial and other research information to ensure it is appropriate for children with cancer and their families.

CCLG Research Network Partner Charity

Represents income research from other charities to fund research projects.

CYP Coalition Activity

Represents income received from charity members of the Children and Young People's Cancer Coalition for the costs of providing the Coalition secretariat.

Neuroblastoma Nursing Group

Represents income received to support the costs of running the national neuroblastoma nursing group, a group of CCLG member nurses with a special interest in neuroblastoma.

Childhood Cancer Priority Setting Partnership

Represents grant income received to support the James Lind Alliance supported Childhood Cancer Priority Setting Partnership being led by CCLG.

PODC - Iraq Fund

Represents donations received to specifically support work to improve the treatment and care of children with cancer in Iraq.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2019

21 Unrestricted funds

The unrestricted funds of the charity include general funds and designated funds which have been set aside out of unrestricted funds by the trustees for specific purposes.

| | Balance at 1 January 2019 £ | Movement in funds | | Transfers £ | Balance at 31 December 2019 £ |
|---------------------------|--------------------------------------|-------------------|--------------------|----------------|--|
| | | Income £ | Expenditure £ | | |
| General funds | 622,964 | 969,632 | (1,089,236) | 2,205 | 505,565 |
| Treatment Guidelines fund | 2,205 | - | - | (2,205) | - |
| | <u>625,169</u> | <u>969,632</u> | <u>(1,089,236)</u> | <u>-</u> | <u>505,565</u> |

| | Balance at 1 January 2018 £ | Movement in funds | | Transfers £ | Balance at 31 December 2018 £ |
|---------------------------|--------------------------------------|-------------------|------------------|----------------|--|
| | | Income £ | Expenditure £ | | |
| General funds | 750,131 | 744,784 | (871,941) | - | 622,964 |
| Treatment Guidelines fund | 2,205 | - | - | - | 2,205 |
| | <u>752,336</u> | <u>744,784</u> | <u>(871,941)</u> | <u>-</u> | <u>625,169</u> |

Treatment Guidelines fund

Represents a sum set aside by the trustees for the development of rare endocrine tumour guidelines.

22 Analysis of net assets between funds

| | Unrestricted funds | | Restricted funds | Total |
|---|--------------------|-----------------|---------------------|------------------|
| | general £ | designated £ | £ | £ |
| Fund balances at 31 December 2019 are represented by: | | | | |
| Tangible assets | 51,150 | - | - | 51,150 |
| Current assets/(liabilities) | 454,415 | - | 3,391,308 | 3,845,723 |
| Long term liabilities | - | - | (2,085,569) | (2,085,569) |
| | <u>505,565</u> | <u>-</u> | <u>1,305,739</u> | <u>1,811,304</u> |

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2019

22 Analysis of net assets between funds

(Continued)

| | Unrestricted funds general £ | designated £ | Restricted funds £ | Total £ |
|---|------------------------------------|-----------------|--------------------------|------------------|
| Fund balances at 31 December 2018 are represented by: | | | | |
| Tangible assets | 37,759 | - | - | 37,759 |
| Current assets/(liabilities) | 585,205 | 2,205 | 1,246,055 | 1,833,465 |
| | <u>622,964</u> | <u>2,205</u> | <u>1,246,055</u> | <u>1,871,224</u> |

23 Operating lease commitments

At the reporting end date the charity had outstanding commitments for future minimum lease payments under non-cancellable operating leases, which fall due as follows:

| | 2019 £ | 2018 £ |
|----------------------------|----------------|-----------|
| Within one year | 27,530 | - |
| Between two and five years | 103,237 | - |
| | <u>130,767</u> | <u>-</u> |

Amounts recognised in profit or loss as an expense during the period in respect of operating lease arrangements are £6,882.

24 Events after the reporting date

The coronavirus (COVID-19) pandemic resulted in fundraising events, meetings and conferences being cancelled after the year end, as a result income after date is expected to reduce significantly. More detail is included in the trustees report on how COVID-19 has impacted the charity and the measures the trustees have taken to try and mitigate its impact.

25 Related party transactions

Remuneration of key management personnel

The remuneration of key management personnel, is as follows.

| | 2019 £ | 2018 £ |
|------------------------|---------------|---------------|
| Aggregate compensation | <u>99,697</u> | <u>67,761</u> |

There have been no other related party transactions in the reporting period that require disclosure in the financial statements, other than those noted in note 11 to the financial statements.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2019

| 26 | Cash generated from operations | 2019 £ | 2018 £ |
|-----------|--|-------------------|-------------------|
| | (Deficit)/surplus for the year | (59,920) | 234,313 |
| | Adjustments for: | | |
| | Investment income recognised in SOFA | (8,841) | (6,193) |
| | Loss on disposal of tangible fixed assets | 30,133 | - |
| | Depreciation and impairment of tangible fixed assets | 9,627 | 14,944 |
| | Movements in working capital: | | |
| | Decrease/(increase) in stocks | 24,915 | (3,149) |
| | (Increase) in debtors | (2,671,531) | (14,684) |
| | Increase/(decrease) in creditors | 2,942,780 | (261,033) |
| | Increase/(decrease) in deferred income | 11,685 | (3,024) |
| | Cash generated from/(absorbed by) operations | 278,848 | (38,826) |

27 Analysis of changes in net debt

The charity had no debt during the year.

THE CHILDREN'S CANCER AND LEUKAEMIA GROUP

NOTES TO THE FINANCIAL STATEMENTS (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2019

28 Merger

On 1 August 2019 the charity converted from an unincorporated charity to a charitable incorporated organisation. The charity's purpose and beneficiary class remained unchanged and the board of trustees has not significantly changed. Therefore the criteria for merger accounting as defined in the FRS 102 SORP has been met and as such this is treated as a merger.

Analysis of principal SoFA components for the current reporting period

| | Unincorporated charity £ | CIO £ | Combined total £ |
|------------------------------|--------------------------------|---------------|------------------------|
| Total income | 2,928,902 | 3,342,862 | 6,271,764 |
| Total expenditure | (3,040,647) | (3,291,037) | (6,331,684) |
| Net income/(expenditure) | (111,745) | 51,825 | (59,920) |
| Other gains/(losses) | - | - | - |
| Net movement in funds | (111,745) | 51,825 | (59,920) |

Analysis of net assets at the date of merger

| | Unincorporated charity £ | CIO £ | Combined total £ |
|--------------------|--------------------------------|---------------|------------------------|
| Net assets | 1,759,479 | 51,825 | 1,811,304 |
| Represented by: | | | |
| Unrestricted funds | 499,800 | 5,765 | 505,565 |
| Restricted funds | 1,259,679 | 46,060 | 1,305,739 |
| Total funds | 1,759,479 | 51,825 | 1,811,304 |